Phathom Pharmaceuticals (PHAT) Cash & Equivalents (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Cash & Equivalents data on file, last reported at $183.8 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $183.8 million, down 14.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $183.8 million (down 14.6% YoY), and the FY2025 annual result was $130.0 million, down 56.69% from the prior year.
• Cash & Equivalents advanced to $183.8 million in Q1 2026 per PHAT's latest filing, from $130.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $384.3 million in Q4 2023 and troughed at $130.0 million in Q4 2025.
• A 5-year average of $220.1 million and a median of $207.9 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 149.92% in 2024, then plunged 59.11% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $155.9 million in 2022, then soared by 146.49% to $384.3 million in 2023, then retreated by 21.89% to $300.1 million in 2024, then slumped by 56.69% to $130.0 million in 2025, then surged by 41.39% to $183.8 million in 2026.
• Business Quant data shows PHAT's Cash & Equivalents at $183.8 million in Q1 2026, $130.0 million in Q4 2025, and $138.0 million in Q3 2025.